Prelude Therapeutics Incorporated (PRLD) compared with its closest peers (EOLS, SPRY, OVID, SGMT, NBP). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Evolus, Inc. (EOLS) | $554.49M | -8.3 |
| ARS Pharmaceuticals, Inc. (SPRY) | $546.17M | -6.7 |
| Ovid Therapeutics Inc. (OVID) | $545.86M | — |
| Sagimet Biosciences Inc. (SGMT) | $544.42M | -3.7 |
| NovaBridge Biosciences (NBP) | $530.76M | -18.9 |
| MapLight Therapeutics, Inc. (MPLT) | $523.89M | -0.9 |
| Evommune, Inc. (EVMN) | $506.27M | -1.6 |
| XOMA Royalty Corp. (XOMA) | $505.65M | 16.8 |
| Rezolute, Inc. (RZLT) | $490.13M | -4.5 |
| Relmada Therapeutics, Inc. (RLMD) | $487.74M | -3.3 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
PRLD overview · PRLD earnings · PRLD financials · PRLD KPIs · PRLD investor relations · PRLD ownership · PRLD filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.